D. Haber

Cell · 2001–2017

A researcher in the Science corpus: 23 papers; trusts 0 researchers and is trusted by 12 researchers here, as inferred from the citation graph.

Who trusts D. Haber overall

1. Nicholas McGranahan
2. Charles Swanton
3. C. Sawyers

Papers from D. Haber's perspective

Ordered by how strongly the researchers D. Haber trusts endorse each paper. Same corpus, a different order for every researcher.

1. Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis (Nature Medicine)
2. Isolation by size of epithelial tumor cells : a new method for the immunomorphological and molecular characterization of circulatingtumor cells. (American Journal of Pathology)
3. Hallmarks of cancer: the next generation. (Cell)
4. Continuous inertial focusing, ordering, and separation of particles in microchannels (Proceedings of the National Academy of Sciences of the United States of America)
5. Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer (Journal of Oncology)
6. Genes that mediate breast cancer metastasis to lung (Nature)
7. Tumor metastasis: mechanistic insights and clinical challenges (Nature Medicine)
8. Systemic spread is an early step in breast cancer. (Cancer Cell)
9. Collective cell migration in morphogenesis, regeneration and cancer
10. AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer (New England Journal of Medicine)

Their papers

• Systematic identification of genomic markers of drug sensitivity in cancer cells (2012) — 2,417 citations
• salvador Promotes both cell cycle exit and apoptosis in Drosophila and is mutated in human cancer cell lines. (2002) — 884 citations
• Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon (2006) — 969 citations
• Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition (2013) — 2,310 citations
• Epidermal growth factor receptor mutations in lung cancer (2007) — 3,159 citations
• A Landscape of Pharmacogenomic Interactions in Cancer (2016) — 1,831 citations
• Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells (2012) — 3,577 citations
• Dual role for argonautes in microRNA processing and posttranscriptional regulation of microRNA expression. (2007) — 709 citations
• Inertial Focusing for Tumor Antigen–Dependent and –Independent Sorting of Rare Circulating Tumor Cells (2013) — 1,059 citations
• Isolation of rare circulating tumour cells in cancer patients by microchip technology (2007) — 3,550 citations
• Correlating chemical sensitivity and basal gene expression reveals mechanism of action (2015) — 798 citations
• BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function. (2001) — 710 citations
• Blood-Based Analyses of Cancer: Circulating Tumor Cells and Circulating Tumor DNA (2014) — 637 citations
• RNA-Seq of Single Prostate CTCs Implicates Noncanonical Wnt Signaling in Antiandrogen Resistance (2015) — 683 citations
• Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway (2017) — 1,715 citations
• Microfluidic, marker-free isolation of circulating tumor cells from blood samples (2014) — 715 citations
• Circulating Tumor Cell Clusters are Oligoclonal Precursors of Breast Cancer Metastasis (2014) — 2,243 citations
• Circulating tumor cells: approaches to isolation and characterization (2011) — 1,085 citations
• First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. (2008) — 865 citations
• Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. (2005) — 972 citations